top of page

Letter of support for drug-induced liver injury (DILI) biomarker

The Drug-Induced Liver Injury (DILI) work package 3 (WP3) of the SAFE-T consortium specifically aimed to address the current lack of sensitive and specific clinical tests to diagnose, predict and monitor drug-induced injury to the liver, which is a major hurdle in drug development.

The objectives of DILI WP3 were to qualify one or a set of new biomarkers with respect to:

- an early or earlier diagnosis of DILI as compared to current diagnostic rules

- the ability to predict DILI outcome, with particular emphasis on severe DILI/acute liver failure

- the prognosis and monitoring of progression and regression of DILI

- the differentiation between patients who incur true drug-induced liver injury from those who recover from the initial injury despite ongoing drug treatment (adaptors).

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page